182 related articles for article (PubMed ID: 16556088)
1. Advances in the treatment for haematological malignancies.
Piccaluga PP; Martinelli G; Baccarani M
Expert Opin Pharmacother; 2006 Apr; 7(6):721-32. PubMed ID: 16556088
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy for haematological malignancies: clinical update from the American Society of Hematology, 2004.
Haas M; Lonial S
Expert Opin Investig Drugs; 2005 Sep; 14(9):1161-9. PubMed ID: 16144500
[TBL] [Abstract][Full Text] [Related]
3. Decade in review-haematological cancer: advances in biology and therapy.
Rajkumar SV; Moreau P
Nat Rev Clin Oncol; 2014 Nov; 11(11):628-30. PubMed ID: 25311345
[No Abstract] [Full Text] [Related]
4. Advancing the treatment of hematologic malignancies through the development of targeted interventions.
Tallman MS
Semin Hematol; 2002 Oct; 39(4 Suppl 3):1-5. PubMed ID: 12447845
[TBL] [Abstract][Full Text] [Related]
5. Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies.
Cao L; Fan L; Xu W; Li JY
Curr Cancer Drug Targets; 2015; 15(9):769-80. PubMed ID: 26567881
[TBL] [Abstract][Full Text] [Related]
6. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic monoclonal antibodies in hemato-oncology].
Gennigens C; Collignon J; Jerusalem G; Rorive A; Sautois B
Rev Med Liege; 2009; 64(5-6):264-7. PubMed ID: 19642456
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy in haematological malignancies.
Hamilton A; Gallipoli P; Nicholson E; Holyoake TL
J Pathol; 2010 Mar; 220(4):404-18. PubMed ID: 20041451
[TBL] [Abstract][Full Text] [Related]
9. A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug.
Arpon DR; Gandhi MK; Martin JH
Br J Clin Pharmacol; 2014 Aug; 78(2):274-81. PubMed ID: 24433338
[TBL] [Abstract][Full Text] [Related]
10. Old disease, new targets. Part-II, haematological malignancies.
Kumar S; Masood N; Adil SN
J Pak Med Assoc; 2009 Aug; 59(8):555-61. PubMed ID: 19757705
[TBL] [Abstract][Full Text] [Related]
11. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.
Chase A; Cross NC
Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463
[TBL] [Abstract][Full Text] [Related]
12. Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies.
Ravandi F; Talpaz M; Estrov Z
Clin Cancer Res; 2003 Feb; 9(2):535-50. PubMed ID: 12576416
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in targeted therapy of human myelogenous leukaemia.
Paz K; Zhu Z
Expert Opin Ther Targets; 2005 Dec; 9(6):1147-63. PubMed ID: 16300467
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies].
Hayashi Y
Gan To Kagaku Ryoho; 2007 Feb; 34(2):194-202. PubMed ID: 17301526
[TBL] [Abstract][Full Text] [Related]
15. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.
Howard SC; Trifilio S; Gregory TK; Baxter N; McBride A
Ann Hematol; 2016 Mar; 95(4):563-73. PubMed ID: 26758269
[TBL] [Abstract][Full Text] [Related]
16. Targeted and tailored therapy in hemato-oncology: vision for the 21st century.
Shpilberg O; Ben-Bassat I; Raanani P
Isr Med Assoc J; 2006 Dec; 8(12):843-4. PubMed ID: 17214100
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy for hematologic malignancies.
Kuriakose P
Cancer Control; 2005 Apr; 12(2):82-90. PubMed ID: 15855891
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults.
Rao AV; Schmader K
Am J Geriatr Pharmacother; 2007 Sep; 5(3):247-62. PubMed ID: 17996665
[TBL] [Abstract][Full Text] [Related]
19. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
20. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
Zhu N; Xiao H; Wang LM; Fu S; Zhao C; Huang H
Future Oncol; 2015; 11(4):659-73. PubMed ID: 25686120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
